Merck and Cardiome announced today that Merck was returning to Cardiome all marketing and development rights for the atrial fibrillation (AF) drug vernakalant. An intravenous formulation of vernakalant is marketed in Europe as Brinavess. It has not been approved in the United States, though it received a positive recommendation from the FDA’s Cardiovascular and Renal…
Merck Returns To Cardiome All Rights To Atrial Fibrillation Drug Vernakalant
September 26, 2012 by Leave a Comment
Merck Drops Development of Oral Vernakalant for Atrial Fibrillation
March 19, 2012 by Leave a Comment
Merck has discontinued its development of oral vernakalant for the long term prevention of atrial fibrillation (AF) recurrence. Cardiome Pharma, Merck’s partner in the drug, said today that the “decision was based on Merck’s assessment of the regulatory environment and projected development timeline.” Merck and Cardiome will continue their partnership with the intravenous formulation of vernakalant,…
Recent Comments